Metraipolis › archive › dc_647512ce3dea

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch… — Europe PMC PMID:42136197

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42136197
DOI
10.1093/jac/dkag172
License (as archived)
solo-consultazione
Archived
2026-11-02T22:08:19.123Z
SHA-256 of the archived text
271d8c117828e3c98860d66c9db7fe7e7ed9ff76271703d1a3c0887f50ec9260
Stable URL of this page
https://metraipolis.com/documento/dc_647512ce3dea

How to cite

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch… — Europe PMC PMID:42136197 — Europe PMC (en), https://europepmc.org/article/MED/42136197 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_647512ce3dea (Metraipolis archive dc_647512ce3dea, sha256 271d8c117828e3c98860d66c9db7fe7e7ed9ff76271703d1a3c0887f50ec9260)
BibTeX
@misc{dc647512ce3dea,
  title = {'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch… — Europe PMC PMID:42136197},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42136197},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_647512ce3dea; sha256 271d8c117828e3c98860d66c9db7fe7e7ed9ff76271703d1a3c0887f50ec9260},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42136197. Agents can read the archived copy with the MCP tool read_document.